Optimized chondrogenesis in an osteochondral defect model (Varidon 2)

ARI Exploratory Research

Background

Bone marrow derived stem (or stromal) cells (BMSCs) have been proposed a source of cells for autologous cell therapy. While showing promise in vitro, translation into the clinics has proven challenging. One reason for this is the inability to accurately predict cell function and hence, whether cells from a patient will behave in a predictable manner. In a previous AO funded study, we defined a TGF beta receptor ratio that was predictive of chondrogenesis. Furthermore, by relatively simple manipulation of the receptor ratio we could convert non-responsive donors and make them responsive to chondrogenic signals. Within this study, we aim to develop this techology further to improve chondrogenic differentiation within biomaterials with implant design in mind. Furthermore, we will activate chondrogenesis by way of multiaxial load, in an ex vivo endochondral defect model that more faithfully resembles a cartilage defect.

 


  • Publication
    Jahangir S, Eglin D, Potter N, Ravari MK, Stoddart MJ, Samadikuchaksaraei A, Alini M, Eslaminejad MB, Safa M. Inhibition of hypertrophy and improving chondrocyte differentiation by MMP-13 inhibitor small molecule encapsulated in alginate-chondroitin sulfate-platelet lysate hydrogel. Stem Cell Res Ther. 2020;11:436.
     
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm